From: The economic burden of systemic sclerosis related pulmonary arterial hypertension in Australia
Patient characteristics at PAH diagnosis | mean ± SD or n(%) | p-value |
---|---|---|
Demographics | ||
Age at PAH diagnosis, years | 63.4 ± 10.4 | |
Disease duration at PAH diagnosisa, years | 14.1 ± 11.6 | |
WHO Functional Class at diagnosis | ||
Class I | 6 (4.5%) | |
Class II | 32 (2.4%) | |
Class III | 82 (62.5%) | |
Class IV | 13 (9.8%) | |
Hemodynamic measurements at PAH diagnosis | ||
6MWD,m | 329.3 ±109.9 | |
mRAP, mmHg | 7.9 ± 3.8 | |
mPAP, mmHg | 33.9 ± 10.9 | |
PAWP, mmHg | 10.9 ± 4.0 | |
mCI, L/min/m2 | 2.9 ± 1.3 | |
PVR, Wood Units | 4.7 ± 2.8 | |
Pericardial effusion at PAH diagnosis | 18 (11.8%) | |
Mean DLCO | 48.9 ± 15.5 | |
Mean DLCO/VA, % predicted mL/min/mmHg | 58.5 ± 19.6 | |
Severe PAHb | 101 (66.0%) | |
Overall survival | 4.8 ± 3.0 | 0.04 |
Time to death from PAH diagnosis, years(n=77) | 4.3 ± 2.7 | |
Survival from PAH diagnosis, years (n=68) | 5.3 ± 3.3 |